Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03687853

Enrollment

Registered

2018-09-27

Start date

2017-01-01

Completion date

2019-12-31

Last updated

2018-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Metastases, Pancreatic Ductal Adenocarcinoma, Who Have High CTCs Count in Portal Venous Blood

Keywords

Pancreatic ductal adenocarcinoma, arterial infusion chemotherapy, liver metastases

Brief summary

Clinical results on intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer

Detailed description

In this study, the investigator try to select 80 patients who received radical surgery for pancreatic cancer, whose circulating tumor cells(CTCs) count then performed on intraoperative portal venous blood to predict postoperative liver metastasis and were divided into two groups. for those who have high CTCs count may have more chance for the occurrence of postoperative liver metastasis was applied hepatic arterial perfusion chemotherapy with minimal dynamic randomization. The aim is to evaluate the feasibility of hepatic arterial infusion chemotherapy for the prevention of postoperative liver metastasis and improvement of prognosis of pancreatic cancer, so as to further improve postoperative management of pancreatic cancer

Interventions

DEVICEIntrahepatic Arterial Infusion

Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Masking description

Pancreatic cancer patients who received chemotherapy through peripheral vein after operation

Intervention model description

Pancreatic cancer patients who received hepatic arterial perfusion chemotherapy after operation

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* pancreatic cancer patients who received the radical operation

Exclusion criteria

* who accepted chemotherapy before operation or who cannot or do not will to accepted enrolled into this study

Design outcomes

Primary

Measure	Time frame	Description
Death	up to 12 months	Overall survival time after operation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026